|
METHOD FOR REDUCING SURFACTANT INACTIVATION IN PULMONARY
SURFACTANT THERAPY
Background:
Human lung surfactant is a complex mixture of lipids and proteins
that reduces surface tension in the lung, enabling normal breathing.
Lack of effective surfactant results in Respiratory Distress Syndrome
(RDS), a potentially fatal condition seen in premature infants and
in adults with lung infection or trauma. While replacement lung
surfactant (RLS) therapy has revolutionized neonatal RDS treatment,
it is relatively ineffective in adults. Even with neonatal RDS,
up to 30% of infants do not respond to RLS therapy. This failure
in RLS therapy has been attributed, at least in part, to inactivation
of the replacement lung surfactant in distressed lungs.
Description:
Researchers at the University of California, San Francisco, have
discovered that inactivation of surfactants by endogenous substances
present in the lung can be significantly reduced by administration
of either ionic or nonionic polymers. Ionic polymers are particularly
effective, and have the advantage that lung epithelial cells produce
them endogenously. The polymers may therefore be useful in the design
of second-generation surfactants for use in RLS.
Advantages:
Addition of the polymers to surfactants may dramatically increase
the effectiveness of replacement lung surfactant therapy.
Applications:
Surfactant with polymer may be useful in the treatment of:
- Respiratory Distress Syndrome of infants and adults.
- Meconium aspiration pneumonia in newborns.
- Acute lung injury.
- Conditions with thick airway secretions such as cystic fibrosis, severe asthma, bronchiectasis, and pneumonia.
Issued Patents: US Patent No. 6,180,142
Case No.: SF98-108
If you would
like to receive further information about this technology and
potential licensing opportunities, please contact:
Sunita Rajdev,
Ph.D.
Licensing Officer
(415) 353-4470 phone
(415) 348-1579 fax
Sunita Rajdev
Reference: OTM Case #SF98-108
|